外貿協會::五金展

BIO PREVENTIVE MEDICINE CORPORATION

6F.-1, No.18, Taiyuan St., Zhubei City, Hsinchu County 302, Taiwan

About us

About BPM
Bio Preventive Medicine (BPM) is a leading company in renal biomarker area. As a clinical staged IVD and biotech company, BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs.

We have obtained CE IVD mark, Malaysia MDA and other regulatory-approvals for global market. BPM is seeking worldwide distribution partner.

For more information, please visit: www.bpmbiotech.com

 

DNlite-IVD103: A novel diagnostic solution for precision management of DKD
Current diagnosis of Diabetic Kidney Disease (DKD) relies on test of Urine Albumin-to-Creatinine Ratio (UACR) and estimation of GFR (eGFR), but they cannot meet the required sensitivity and specificity to predict and identify DKD patients who will progress, which is crucial for DKD management. Besides, UACR doesn’t well correlated with DKD, and eGFR is a late biomarker of disease progression. 

 

DNlite-IVD103 is an urinary ELISA kit that precisely manages DKD. By detecting a specific urinary biomarker and meticulously monitoring for post translational modifications to the marker, DNlite-IVD103 can effectively predict the kidney condition of a diabetes patient over the 1-2 years that follow. If a risk of progressive GFR decline is detected, patients can be recommended to start proper treatment earlier, and seize a critical window for clinical action and even recovery. Prediction and monitoring of decline or kidney complications will drastically improve the DKD patient’s quality of care. 

 

  • DNlite-IVD103 is a better predictor to identify patients who will progress

 

  • Features of DNlite-IVD103

About BPM
Bio Preventive Medicine (BPM) is a leading company in renal biomarker area. As a clinical staged IVD and biotech company, BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs.

We have obtained CE IVD mark, Malaysia MDA and other regulatory-approvals for global market. BPM is seeking worldwide distribution partner.

For more information, please visit: www.bpmbiotech.com

 

DNlite-IVD103: A novel diagnostic solution for precision management of DKD
Current diagnosis of Diabetic Kidney Disease (DKD) relies on test of Urine Albumin-to-Creatinine Ratio (UACR) and estimation of GFR (eGFR), but they cannot meet the required sensitivity and specificity to predict and identify DKD patients who will progress, which is crucial for DKD management. Besides, UACR doesn’t well correlated with DKD, and eGFR is a late biomarker of disease progression. 

 

DNlite-IVD103 is an urinary ELISA kit that precisely manages DKD. By detecting a specific urinary biomarker and meticulously monitoring for post translational modifications to the marker, DNlite-IVD103 can effectively predict the kidney condition of a diabetes patient over the 1-2 years that follow. If a risk of progressive GFR decline is detected, patients can be recommended to start proper treatment earlier, and seize a critical window for clinical action and even recovery. Prediction and monitoring of decline or kidney complications will drastically improve the DKD patient’s quality of care. 

  • DNlite-IVD103 is a better predictor to identify patients who will progress

 

  • Features of DNlite-IVD103

Products

Disease Detection

DNlite-IVD103 ELISA Kit

DNlite-IVD103:

DNlite-IVD103 is a urinary ELISA kit that precisely manages DKD. By detecting and monitoring a unique biomarker with specific post translational modification (PTM), DNlite-IVD103 can effectively predict the kidney condition of a diabetic patient over the 1-2 years that follow.

Disease Detection

DNlite-IVD103 ELISA Kit

DNlite-IVD103:

DNlite-IVD103 is a urinary ELISA kit that precisely manages DKD. By detecting and monitoring a unique biomarker with specific post translational modification (PTM), DNlite-IVD103 can effectively predict the kidney condition of a diabetic patient over the 1-2 years that follow.